Selective Genetics Announces Exclusive License to Gene Transfer Patent

Strategic Insights -

Selective Genetics, Inc. has acquired the exclusive license to U.S. Patent Number 5,763,416, "Gene transfer into bone cells and tissues," which was issued to the University of Michigan on June 9, 1998. The patent covers the company's Gene Activated Matrix (GAM) technology for delivering genes into sites of tissue repair, including bone. This technology has significant potential for the treatment of various conditions, including bone growth and tissue regeneration. By leveraging this patent, Selective Genetics aims to enter into limited licensing and collaboration agreements for commercialization of products employing its GAM technology.

Key Takeaways:

  • Selective Genetics, Inc. has acquired the exclusive license to U.S. Patent Number 5,763,416, "Gene transfer into bone cells and tissues."
  • The patent was issued to the University of Michigan on June 9, 1998, and broadly covers the company's Gene Activated Matrix (GAM) technology.
  • The GAM technology enables the delivery of genes into sites of tissue repair, including bone, and has potential applications in treating various conditions.
  • Robert T. Abbott, Chief Executive Officer of Selective Genetics, stated that delivery of growth factors via gene transfer is a more rational approach to tissue repair than direct delivery of growth factors as proteins.
  • GAM technology can produce several weeks of growth factor expression within tissue repair sites, whereas directly-delivered proteins rarely last more than a day or two.
  • Selective Genetics intends to enter into limited licensing and collaboration agreements for commercialization of products employing its GAM technology.
  • The company is developing site-specific gene therapies primarily for tissue repair and regeneration.
  • Selective Genetics, Inc. is the first biotechnology company to focus on gene therapy for tissue repair and regeneration.

Statistics:

  • U.S. Patent Number 5,763,416 was issued to the University of Michigan on June 9, 1998.
  • The GAM technology has the potential to treat various conditions, including bone growth and tissue regeneration.
  • Selective Genetics, Inc. plans to enter into a limited number of licensing and collaboration agreements for commercialization of products employing its GAM technology.
  • The company's patent covers methods for delivering therapeutic genes via matrix carriers to bone progenitor cells or fibroblast cells at tissue repair sites.
  • The patent also covers the gene therapy use of specific genes related to bone growth and tissue regeneration.

Sources:

  • PRNewswire, "Selective Genetics Announces Exclusive License to Gene Transfer Patent" (July 10, 1998)
  • U.S. Patent Number 5,763,416, "Gene transfer into bone cells and tissues"
  • Selective Genetics, Inc. press release